Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight

Clinical trial NCT04306315 · COMPLETED

Trial details

NCT number: NCT04306315
Sponsor: LEO Pharma
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Psoriasis Vulgaris

Start date: 2022-07-21
Primary completion: 2025-08-25
Enrollment: 385

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.